Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
source: pixabay.com

Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis

  According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…

Continue Reading Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
Study Confirms the Superiority of Rituximab (Rituxan) in Treating Pemphigus Vulgaris
stevepb / Pixabay

Study Confirms the Superiority of Rituximab (Rituxan) in Treating Pemphigus Vulgaris

According to a story from marketscreener.com, the biotechnology company Roche recently announced the results from a company sponsored phase 3 clinical trial that compared the safety and efficacy of rituximab…

Continue Reading Study Confirms the Superiority of Rituximab (Rituxan) in Treating Pemphigus Vulgaris

Positive Results from Phase 2 Trial Could Lead to Lower Doses of Corticosteroids for Pemphigus Patients

Pemphigus Pemphigus is a rare autoimmune condition which causes the skin to blister. There are two main forms of the disease called pemphigus foliaceus (PF) and pemphigus vulgaris (PV). Pemphigus…

Continue Reading Positive Results from Phase 2 Trial Could Lead to Lower Doses of Corticosteroids for Pemphigus Patients
First Major Treatment Advance for PV Has Been Approved by the FDA
Source: pixabay.com

First Major Treatment Advance for PV Has Been Approved by the FDA

  According to BioSpace, a new treatment for pemphigus vulgaris (PV) has been recently approved by the U.S. Food and Drug Administration. The treatment, Rituxan (rituximab), is geared towards adults who have…

Continue Reading First Major Treatment Advance for PV Has Been Approved by the FDA